Our results also have implications for ongoing clinical trials of cancer nanomedicines, as they describe how TGF‐β inhibition can normalize metastases and in turn improve nanocarrier efficacy to metastatic breast cancer and stimulate anti‐tumor immune responses. Here, TGFB1 is linked to breast carcinoma.